XM levert geen diensten aan inwoners van de Verenigde Staten.

XM levert geen diensten aan inwoners van de Verenigde Staten.
G
G

Gilead

Nieuws

Reuters - 10 uur geleden

Gilead gets US FDA approval for inflammatory liver disease drug

UPDATE 3-Gilead gets US FDA approval for inflammatory liver disease drug Adds pricing in paragraph 4, company comments in paragraphs 6-7, details on common symptom in paragraphs 10-12 By Puyaan Singh and Leroy Leo Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year.
G
I
Reuters - 10 uur geleden

FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website

BRIEF-FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website Aug 14 (Reuters) - FDA: FDA APPROVES GILEAD'S LIVDELZI FOR PRIMARY BILIARY CHOLANGITIS - WEBSITE Further company coverage: GILD.O
G
Reuters - 10 uur geleden

US FDA approves Gilead's liver disease drug

US FDA approves Gilead's liver disease drug Aug 14 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' GILD.O drug for a chronic and potentially fatal liver disease that mostly affects women. The disease, primary biliary cholangitis (PBC), causes inflammation of the small bile ducts in the liver and can eventually destroy them.
G
Reuters - 6 dagen geleden

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary Gilead Sciences Inc GILD.OQ reported quarterly adjusted earnings of $2.01​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.66. The mean expectation of twenty three analysts for the quarter was for earnings of $1.60 per share.
G
Reuters - 6 dagen geleden

Gilead quarterly profit beats Street estimates, revenue up 5%

UPDATE 1-Gilead quarterly profit beats Street estimates, revenue up 5% Adds analyst comment, share price, paragraphs 4-6 By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
G
Reuters - 6 dagen geleden

Gilead quarterly profit beats Street estimates, revenue up 5%

Gilead quarterly profit beats Street estimates, revenue up 5% By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings. The Foster City, California-based company posted a quarterly profit of $2.01 per share excluding items, on revenue of $7 billion, up from $1.34 a share and revenue of $6.6 bi
G
Reuters - 6 dagen geleden

Gilead Q2 EPS USD 1.29

BRIEF-Gilead Q2 EPS USD 1.29 Aug 08 (Reuters) - Gilead Q2 product sales USD 6,912 million. Q2 operating income USD 2,644 million Q2 pretax profit USD 2,053 million vs. IBES estimate USD 2,593 million Q2 net income USD 1,614 million Q2 basic EPS USD 1.29
G
Reuters - 1 week geleden

Merck stops testing combo drug for lung cancer

UPDATE 1-Merck stops testing combo drug for lung cancer Adds details in paragraphs 2 and 6, background throughout Aug 8 (Reuters) - Merck MRK.N said on Thursday it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed. The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck sa
G
Reuters - 1 week geleden

Markets stay bumpy awaiting jobs reality check

MORNING BID AMERICAS-Markets stay bumpy awaiting jobs reality check A look at the day ahead in U.S. and global markets from Mike Dolan Seeking some calm, markets remain edgy following the volatility jolt of the past week and traders now seek some re-assurance the real economy has not shifted underneath them. Volatility spikes like the one seen on Monday rarely disappear instantly and, with the VIX 'fear gauge' .VIX still above historical averages of about 20 , some turbulence remains.
A
E
G
N
N
U
T
J
U
U
U
F
M
Reuters - 1 week geleden

What to Watch in the Day Ahead - Thursday, August 8

What to Watch in the Day Ahead - Thursday, August 8 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT The Labor Department's weekly jobless claims report will be widely watched by investors after weaker-than-expected July jobs data last week fueled to a stock market rout.
G
N
Reuters - 1 week geleden

Gilead Sciences Inc <GILD.OQ> expected to post earnings of $1.60 a share - Earnings Preview

Gilead Sciences Inc expected to post earnings of $1.60 a share - Earnings Preview Gilead Sciences Inc GILD.OQ GILD.O is expected to show a rise in quarterly revenue when it reports results on August 8 for the period ending June 30 2024 The Foster City California-based company is expected to report a 1.8% increase in revenue to $6.719 billion from $6.6 billion a year ago, according to the mean estimate from 21 analysts, based on LSEG data.
G
Reuters - 3 weken geleden

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Atlassian Corp TEAM.OQ +7.4% Old Dominion Freight Line Inc ODFL.OQ +5.8% MongoDB Inc MDB.OQ +5.7% O'Reilly Automotive Inc ORLY.OQ +4.3% Gilead Sciences Inc GILD.OQ +4.0% Bottom Performers Percent Change Lululemon Athletica Inc LULU.OQ -8.2% Warner Bros Discovery Inc WBD.OQ -5.4% Honeywell International Inc HON.OQ -4.9% Arm Holdings PLC ARM.OQ -4.6% Booking Holdings Inc BKNG.OQ -3.
G
L
U
A
B
O
Reuters - 3 weken geleden

Gilead climbs on positive data from HIV drug trial

BUZZ-Gilead climbs on positive data from HIV drug trial ** Shares of drugmaker Gilead Sciences GILD.O rise ~2.6% to $73.05 ** Co says its HIV prevention drug Lenacapavir showed zero infections and 100% efficacy and superiority against a daily dose of its HIV treatment Truvada ** Says patients showed high adherence to the injectable drug during the late-stage trial ** "We see GILD's HIV business supporting most, if not all, of the company's current market cap" say analysts at J.P.
G
Reuters - 3 weken geleden

Pharma aims to deliver personalized cancer therapies more quickly

FOCUS-Pharma aims to deliver personalized cancer therapies more quickly By Michael Erman NEW YORK, July 24 (Reuters) - Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they try to deliver them sooner in a patient's disease course.
G
N
Reuters - 1 maand geleden

U.S. STOCKS Gold miners, Nikola, Cruise stocks

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Nikola, Cruise stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Chip stocks boosted the Nasdaq on Monday, while the S&P 500 and the Dow edged lower as investors awaited a key inflation reading, commentary from Federal Reserve Chair Jerome Powell and the start of corporate earnings season for monetary policy cues.
C
G
I
J
N
Q
T
U
U
R
S
V
F
M
Reuters - 1 maand geleden

U.S. STOCKS Ally Financial, Ideaya Biosciences, Brinker

BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Ideaya Biosciences, Brinker Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 hit record highs on Monday, while the Dow scaled a more than one-month high as investors awaited a key inflation report, Congressional testimony from Federal Reserve Chair Jerome Powell and the start of earnings season this week.
B
C
G
I
J
N
Q
T
U
U
H
S
V
F
M
Reuters - 1 maand geleden

U.S. STOCKS Boeing, Gilead Sciences, Bumble

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Gilead Sciences, Bumble Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were on track for a listless open on Monday, in a week packed with crucial inflation readings, Congressional testimony from Federal Reserve Chair Jerome Powell and the start of the corporate earnings season.
B
G
T
U
H
S
F
Reuters - 1 maand geleden

Gilead Sciences rises as brokerage upgrades to 'outperform'

BUZZ-Gilead Sciences rises as brokerage upgrades to 'outperform' ** Gilead Sciences' GILD.O shares rise 3.1% to $68.74 premarket ** Brokerage Raymond James raises its rating on company's shares to "outperform" from "market perform" ** Outstanding data from a study of Gilead's long-acting drug lenacapavir in HIV and expected approval of liver diseas
G
Reuters - 1 maand geleden

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - 1 maand geleden

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Paramount Global PARA.OQ +6.9% First Solar Inc FSLR.OQ +6.6% Tesla Inc TSLA.OQ +6.5% Vistra Corp VST.N +4.6% NVIDIA Corp NVDA.OQ +4.6% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Constellation Brands Inc
G
N
T
W
U

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.